26rhk193 10.3205/26rhk193 urn:nbn:de:0183-26rhk1932 Meeting Abstract Pongratz Pongratz Georg G

Abteilung für Rheumatologie und klinische Immunologie, Krankenhaus Barmherzige Brüder Regensburg und Fakultät für Medizin, Universität Regensburg, Regensburg, Deutschland

author Witte Witte Torsten T

Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover, Deutschland

author Alten Alten Rieke R

Schlosspark-Klinik, Akademisches Lehrkrankenhaus der Charité – Universitätsmedizin Berlin, Berlin, Deutschland

author Pausch Pausch Christine C

Innovationszentrum Real-World Evidence, GWT-TUD GmbH, Dresden, Deutschland

author Reinhold Reinhold Robert R

Medizinische Abteilung, Alfasigma GmbH, München, Deutschland

author Pittrow Pittrow David D

Innovationszentrum Real-World Evidence, GWT-TUD GmbH, Dresden, Deutschland Institut für Klinische Pharmakologie, Medizinische Fakultät, Technische Universität Dresden, Dresden, Deutschland

author Burmester Burmester Gerd-Rüdiger GR

Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

author German Medical Science GMS Publishing House

Düsseldorf

610 20260909 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0656 193 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie Gesellschaft für Kinder- und Jugendrheumatologie 54. Kongress der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie (DGRh), 36. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR), 40. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2026 Rheumatoide Arthritis Leipzig 20260909 20260912 RA.07 TextIntroduction: Filgotinib is an oral, JAK1-preferential inhibitor approved for moderate-to-severe rheumatoid arthritis (RA). While efficacy is established in randomized trials, very early real-world changes in pain and other patient-reported outcomes (PROs) need additional attention. We aim to describe baseline characteristics and prior RA therapies of patients initiating filgotinib in FIRST-RA and to assess very early changes in pain and other Rheumatoid Arthritis Impact of Disease (RAID) domains over the first 4 weeks.Methods: FIRST-RA (DRKS00036136) is an ongoing, prospective, multicenter, non-interventional cohort study in Germany and Austria enrolling adults with active RA starting filgotinib per label. Clinical data are collected at baseline and Weeks 4, 12, and 24. PROs (RAID, including pain and fatigue) are recorded at baseline (Day 0), daily on Days 1-7, and weekly up to Week 4. This descriptive interim analysis uses a data cut of February 23, 2026 (n=126). Patients were grouped by prior advanced therapy (AT; bDMARD/tsDMARD): 0, 1, or ≥2.Results: Mean (SD) age was 54.7 (13.3) years; 76.2% were female; mean BMI was 27.9 (5.4) kg/m²; mean RA duration 8.6 (9.0) years; baseline DAS28-CRP 4.0 (1.1). Prior therapies were common (methotrexate 88.8%, leflunomide 44.8%); 54.4% had received a TNF inhibitor (Figure 1 ). Prior AT exposure: 43.0% none, 36.4% one, 20.7% ≥2. Filgotinib was most often used as monotherapy; one quarter (24.5%) received combination with a csDMARD. Mean (SD) RAID pain score was 5.9 (2.1) at baseline; mean change was −0.7 (1.2) at Day 3, −1.7 (1.7) at Day 7, and −2.8 (2.4) at Week 4 (Figure 2 ). Pain responders (≥ 1-point decrease) increased from 50.5% (Day 3) to 78.3% (Day 7) and 85.9% (Week 4). Similar improvements were observed for RAID fatigue and total score.Conclusion: In routine care, patients initiating filgotinib showed rapid, clinically meaningful pain relief within the first week, with continued improvement through Week 4, mirrored by reductions in fatigue and overall RAID scores.Acknowledgements: We thank the physicians and patients who participated in the study. The FIRST-RA study was sponsored by Alfasigma GmbH (Munich, Germany).Disclosure of interest: Georg Pongratz Paid instructor: Eli Lilly, Speakers bureau: AbbVie, Alfasigma, Boehringer Ingelheim, Eli Lilly & Co., Galapagos, Pfizer, Roche, Sanofi, Viatris and Vertanical, Consultant: AbbVie, Alfasigma, Boehringer Ingelheim, Eli Lilly & Co., Galapagos, Pfizer, Roche, Sanofi, Viatris and Vertanical.Rieke Alten Speakers bureau: AbbVie, Alfasigma, Amgen, Biogen, BMS, Celltrion, Chugai, Eli Lilly & Co., Galapagos, Gilead, Hexal, Janssen, Novartis, Pfizer, Roche, UCB and Viatris, Consultant: AbbVie, Alfasigma, Amgen, Biogen, BMS, Celltrion, Chugai, Eli Lilly & Co., Galapagos, Gilead, Hexal, Janssen, Novartis, Pfizer, Roche, UCB and ViatrisTorsten Witte Speakers bureau: AbbVie, Alfasigma, Eli Lilly & Co. and Pfizer, Consultant: AbbVie, Alfasigma, Eli Lilly & Co. and Pfizer.Christine Pausch: None declared.Robert Reinhold Employee: Alfasigma GmbH.David Pittrow Consultant: Alfasigma, Amgen, Aspen, Bayer, Boehringer Ingelheim, MSD, Sandoz/Hexal and Viatris.Gerd R. Burmester Speakers bureau: AbbVie, Alfasigma, BMS, Eli Lilly & Co., Galapagos, Janssen, Novartis, Pfizer, Sanofi and UCB, Consultant: AbbVie, Alfasigma, BMS, Eli Lilly & Co., Galapagos, Janssen, Novartis, Pfizer, Sanofi and UCB 0

1 1 Figure 1: Therapy immediately prior to filgotinib initiation and at start of study documentation

2 2 Figure 2: Mean change in RAID pain score (0-10) over 28 days after filgotinib initiation; numbers above the x-axis indicate the sample size at each time point

2 0 0